Alvimopan

What is Alvimopan?

Alvimopan is a medication primarily used to accelerate the recovery of gastrointestinal (GI) function following certain types of surgery. Specifically, it is a peripherally acting mu-opioid receptor antagonist. This means it works by blocking the effects of opioids in the gut without crossing the blood-brain barrier, thereby avoiding interference with central pain relief provided by opioid analgesics. Marketed under the brand name Entereg, it plays a crucial role in managing postoperative ileus (POI), a common complication where normal bowel function slows down after abdominal surgery, helping patients return to normal eating and discharge sooner.

How Does it Work?

The mechanism of action for Alvimopan centers on its role as a selective antagonist of mu-opioid receptors found in the gastrointestinal tract. Opioid medications, commonly used for pain management after surgery, bind to these receptors, leading to decreased gut motility, reduced secretions, and increased sphincter tone. These effects contribute significantly to the development of postoperative ileus (POI). By blocking these mu-opioid receptors, Alvimopan effectively counteracts the inhibitory effects of opioids on the gut. It restores and promotes normal bowel function, allowing the digestive system to resume its natural rhythm more quickly. Crucially, as Alvimopan does not readily cross the blood-brain barrier, it doesn't interfere with central pain relief, ensuring patients continue adequate pain management while their GI tract recovers.

Medical Uses

The primary medical use for Alvimopan is to shorten the time to upper and lower gastrointestinal (GI) recovery following partial small or large bowel resection surgery. This medication is indicated for adult hospitalized patients who have undergone such procedures. Postoperative ileus (POI) is a significant concern after these surgeries, leading to discomfort, prolonged hospital stays, and increased healthcare costs. By accelerating the return of normal bowel function, Alvimopan helps to mitigate these issues. It enables patients to tolerate oral intake sooner, reduces the need for nasogastric tube decompression, and contributes to an earlier hospital discharge. Its targeted action makes it an important tool in enhanced recovery after surgery (ERAS) protocols.

Dosage

Alvimopan is administered orally, typically as a 12 mg capsule. The standard dosage regimen involves giving the first dose 30 minutes to 5 hours prior to surgery. Subsequent doses of 12 mg are then administered twice daily starting the day after surgery. Treatment with Alvimopan is generally limited to a maximum of 7 days or 15 doses, whichever comes first. It's important to note that Alvimopan is part of a Risk Evaluation and Mitigation Strategy (REMS) program and is only available to hospitals that enroll in the program. This ensures safe and appropriate use, particularly given certain risks. Dosage adjustments are generally not required for mild to moderate renal or hepatic impairment, but healthcare providers should always assess individual patient circumstances.

Side Effects

Like all medications, Alvimopan can cause side effects, although not everyone experiences them. Common side effects reported include dyspepsia (indigestion), abdominal pain, nausea, vomiting, and flatulence. These are generally mild and transient. More serious, though rare, side effects have been observed. A significant concern, contributing to the REMS program, is a potential increased risk of myocardial infarction (heart attack) in patients receiving therapeutic doses of opioids for more than 7 consecutive days prior to surgery. Hence, Alvimopan is contraindicated in such patients. Patients should always discuss their full medical history and current medications with their healthcare provider to ensure Alvimopan is a safe and appropriate treatment option.

Drug Interactions

The primary consideration for drug interactions with Alvimopan revolves around its intended purpose and mechanism. While it is designed to counteract the peripheral effects of opioids, it is contraindicated in patients who have been on chronic opioid therapy (more than 7 consecutive days immediately prior to surgery) due to the potential increased risk of myocardial infarction. Beyond this, Alvimopan has a relatively low potential for significant drug-drug interactions. It is primarily eliminated unchanged in the feces and does not appear to be extensively metabolized by cytochrome P450 enzymes. Its limited systemic absorption and peripheral action also contribute to a lower risk of interactions. However, patients must always inform their healthcare team about all medications and supplements to avoid unforeseen interactions.

FAQ

• Q: Is Alvimopan an opioid?
  A: No, Alvimopan is not an opioid. It is a peripherally acting mu-opioid receptor antagonist, meaning it blocks the effects of opioids in the gastrointestinal tract without having opioid-like effects itself.
• Q: Can I take Alvimopan at home?
  A: No, Alvimopan is only available through a restricted distribution program (REMS) and is administered exclusively in hospitals. It is not intended for outpatient use.
• Q: How quickly does Alvimopan work?
  A: Alvimopan helps to accelerate the return of normal bowel function after surgery. While individual results vary, it is designed to shorten the time to gastrointestinal (GI) recovery by several days compared to placebo.
• Q: What is Entereg?
  A: Entereg is the brand name for the generic medication Alvimopan. They are the same drug.
• Q: What is postoperative ileus (POI)?
  A: Postoperative ileus (POI) is a temporary cessation or reduction of normal intestinal motility that commonly occurs after abdominal surgery, leading to symptoms like nausea, vomiting, abdominal distension, and inability to pass gas or stool.

Products containing Alvimopan are available through trusted online pharmacies. You can browse Alvimopan-based medications at ShipperVIP or Medicenter.

Summary

Alvimopan is a vital medication used in the perioperative setting to enhance patient recovery. As a peripherally acting mu-opioid receptor antagonist, it specifically targets and blocks opioid receptors in the gastrointestinal tract, counteracting the slowing effects of opioid pain medications on the gut. Its primary indication is to accelerate gastrointestinal (GI) recovery following partial small or large bowel resection surgery, thereby reducing the duration and severity of postoperative ileus (POI). By promoting faster return of normal bowel function, Alvimopan contributes to shorter hospital stays and improved patient comfort. Administered under strict hospital protocols due to its REMS program, it offers a targeted strategy for managing common post-surgical complications, ensuring a smoother recovery.